Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Terns Pharmaceuticals Inc
(NQ:
TERN
)
5.790
+0.080 (+1.40%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Terns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
June 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
8 Analysts Have This to Say About Terns Pharma
May 31, 2023
Via
Benzinga
Expert Ratings for Terns Pharma
May 08, 2023
Via
Benzinga
Why Shares of Terns Pharmaceuticals Soared This Week
March 30, 2023
The company is showing progress toward a NASH therapy.
Via
The Motley Fool
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
May 25, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
May 24, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 23, 2023
Gainers
Via
Benzinga
The Latest Analyst Ratings for Terns Pharma
March 29, 2023
Via
Benzinga
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
May 22, 2023
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
May 15, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 16, 2023
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
May 08, 2023
Via
Benzinga
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 28, 2023
Via
Benzinga
Why Terns Pharmaceuticals Shares Are Trading Higher Today
March 28, 2023
Terns Pharmaceuticals (NASDAQ: TERN) shares are trading higher on Tuesday after the company reported Q4 financial results.
Via
Benzinga
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 27, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
March 27, 2023
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
March 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
February 14, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2023
February 07, 2023
Via
Benzinga
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
February 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 01, 2023
Via
Benzinga
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 12, 2023
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity...
Via
Benzinga
CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
January 11, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
December 29, 2022
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.